SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Accelerated Pharma, Inc. – ‘10-Q’ for 9/30/19 – ‘EX-101.SCH’

On:  Wednesday, 4/22/20, at 12:44pm ET   ·   For:  9/30/19   ·   Accession #:  1493152-20-6905   ·   File #:  333-227916

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/22/20  Accelerated Pharma, Inc.          10-Q        9/30/19   39:1.6M                                   M2 Compliance/FA

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    191K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     17K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     17K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     15K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     15K 
23: R1          Document and Entity Information                     HTML     44K 
36: R2          Condensed Consolidated Balance Sheets               HTML     83K 
29: R3          Condensed Consolidated Balance Sheets               HTML     39K 
                (Parenthetical)                                                  
15: R4          Condensed Consolidated Statements of Operations     HTML     54K 
                and Comprehensive Loss (Unaudited)                               
24: R5          Condensed Consolidated Statements of Changes in     HTML     60K 
                Stockholders' Deficiency (Unaudited)                             
37: R6          Condensed Consolidated Statements of Cash Flows     HTML     72K 
                (Unaudited)                                                      
30: R7          Business                                            HTML     21K 
14: R8          Going Concern and Management's Liquidity Plans      HTML     21K 
26: R9          Significant Accounting Policies                     HTML     36K 
19: R10         Out-of-Period Adjustment                            HTML     18K 
17: R11         Convertible Debt                                    HTML     21K 
27: R12         Notes Payable - Related Party                       HTML     16K 
38: R13         Stockholders' Equity                                HTML     18K 
20: R14         Subsequent Events                                   HTML     20K 
18: R15         Significant Accounting Policies (Policies)          HTML     58K 
28: R16         Significant Accounting Policies (Tables)            HTML     27K 
39: R17         Business (Details Narrative)                        HTML     15K 
22: R18         Going Concern and Management's Liquidity Plans      HTML     27K 
                (Details Narrative)                                              
16: R19         Significant Accounting Policies - Schedule of       HTML     18K 
                Foreign Currency Translation Exchange Rate                       
                (Details)                                                        
31: R20         Significant Accounting Policies - Schedule of       HTML     25K 
                Potentially Dilutive Securities Excluded from                    
                Computation of Net Loss Per Share (Details)                      
34: R21         Out-of-Period Adjustment (Details Narrative)        HTML     38K 
25: R22         Convertible Debt (Details Narrative)                HTML     39K 
13: R23         Notes Payable - Related Party (Details Narrative)   HTML     19K 
32: R24         Stockholders' Equity (Details Narrative)            HTML     28K 
35: R25         Subsequent Events (Details Narrative)               HTML     48K 
21: XML         IDEA XML File -- Filing Summary                      XML     61K 
33: EXCEL       IDEA Workbook of Financial Reports                  XLSX     32K 
 6: EX-101.INS  XBRL Instance -- accp-20190930                       XML    379K 
 8: EX-101.CAL  XBRL Calculations -- accp-20190930_cal               XML     79K 
 9: EX-101.DEF  XBRL Definitions -- accp-20190930_def                XML    241K 
10: EX-101.LAB  XBRL Labels -- accp-20190930_lab                     XML    352K 
11: EX-101.PRE  XBRL Presentations -- accp-20190930_pre              XML    319K 
 7: EX-101.SCH  XBRL Schema -- accp-20190930                         XSD     66K 
12: ZIP         XBRL Zipped Folder -- 0001493152-20-006905-xbrl      Zip     47K

‘EX-101.SCH’   —   XBRL Schema — accp-20190930

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3a -->
<!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
<!-- Field: Doc-Info; Name: Source; Value: ACCP 20190930 10Q Q3 DFN.xfr; Date: 2020%2D04%2D22T16:15:37Z -->
<!-- Field: Doc-Info; Name: Status; Value: 0x800B0000 -->
<!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaWLObP9z5Z8SekhvWB7bYlqDyEtDAmM6StOMMXWIXwN -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ACCP="http://apipharmaceuticals.com/20190930" elementFormDefault="qualified" targetNamespace="http://apipharmaceuticals.com/20190930">
<annotation>
<appinfo>
<link:roleType roleURI="http://apipharmaceuticals.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition> 00000001 - Document - Document and Entity Information </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/BalanceSheets" id="BalanceSheets">
<link:definition> 00000002 - Statement - Condensed Consolidated Balance Sheets </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
<link:definition> 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
<link:definition> 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/StatementsOfChangesInStockholdersDeficiency" id="StatementsOfChangesInStockholdersDeficiency">
<link:definition> 00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Deficiency (unaudited) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
<link:definition> 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/Business" id="Business">
<link:definition> 00000007 - Disclosure - Business </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/GoingConcernAndManagementsLiquidityPlans" id="GoingConcernAndManagementsLiquidityPlans">
<link:definition> 00000008 - Disclosure - Going Concern and Management's Liquidity Plans </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
<link:definition> 00000009 - Disclosure - Significant Accounting Policies </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/Out-of-periodAdjustment" id="Out-of-periodAdjustment">
<link:definition> 00000010 - Disclosure - Out-of-Period Adjustment </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/ConvertibleDebt" id="ConvertibleDebt">
<link:definition> 00000011 - Disclosure - Convertible Debt </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/NotesPayable-RelatedParty" id="NotesPayable-RelatedParty">
<link:definition> 00000012 - Disclosure - Notes Payable - Related Party </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition> 00000013 - Disclosure - Stockholders' Equity </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition> 00000014 - Disclosure - Subsequent Events </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
<link:definition> 00000015 - Disclosure - Significant Accounting Policies (Policies) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
<link:definition> 00000016 - Disclosure - Significant Accounting Policies (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/BusinessDetailsNarrative" id="BusinessDetailsNarrative">
<link:definition> 00000017 - Disclosure - Business (Details Narrative) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/GoingConcernAndManagementsLiquidityPlansDetailsNarrative" id="GoingConcernAndManagementsLiquidityPlansDetailsNarrative">
<link:definition> 00000018 - Disclosure - Going Concern and Management's Liquidity Plans (Details Narrative) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/SignificantAccountingPolicies-ScheduleOfForeignCurrencyTranslationExchangeRateDetails" id="SignificantAccountingPolicies-ScheduleOfForeignCurrencyTranslationExchangeRateDetails">
<link:definition> 00000019 - Disclosure - Significant Accounting Policies - Schedule of Foreign Currency Translation Exchange Rate (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/SignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfNetLossPerShareDetails" id="SignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfNetLossPerShareDetails">
<link:definition> 00000020 - Disclosure - Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Computation of Net Loss Per Share (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/Out-of-periodAdjustmentDetailsNarrative" id="Out-of-periodAdjustmentDetailsNarrative">
<link:definition> 00000021 - Disclosure - Out-of-Period Adjustment (Details Narrative) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/ConvertibleDebtDetailsNarrative" id="ConvertibleDebtDetailsNarrative">
<link:definition> 00000022 - Disclosure - Convertible Debt (Details Narrative) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/NotesPayable-RelatedPartyDetailsNarrative" id="NotesPayable-RelatedPartyDetailsNarrative">
<link:definition> 00000023 - Disclosure - Notes Payable - Related Party (Details Narrative) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
<link:definition> 00000024 - Disclosure - Stockholders' Equity (Details Narrative) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://apipharmaceuticals.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
<link:definition> 00000025 - Disclosure - Subsequent Events (Details Narrative) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="accp-20190930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links"/>
<link:linkbaseRef xlink:type="simple" xlink:href="accp-20190930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links"/>
<link:linkbaseRef xlink:type="simple" xlink:href="accp-20190930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links"/>
<link:linkbaseRef xlink:type="simple" xlink:href="accp-20190930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links"/>
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
<import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
<import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
<import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
<import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd"/>
<element id="ACCP_AdjustmentsToAdditionalPaidInCapitalReclassifyDerivativeLiabilityToEquity" name="AdjustmentsToAdditionalPaidInCapitalReclassifyDerivativeLiabilityToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_IncreaseDecreaseInAccruedCompensation" name="IncreaseDecreaseInAccruedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_ReclassifyFairValueOfWarrantLiabilitiesToEquity" name="ReclassifyFairValueOfWarrantLiabilitiesToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_OutofperiodAdjustmentTextBlock" name="OutofperiodAdjustmentTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_NotesPayableRelatedPartyTextBlock" name="NotesPayableRelatedPartyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_PrepaymentPremiumPercentage" name="PrepaymentPremiumPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_ProceedsFromUnitOffering" name="ProceedsFromUnitOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_SeriesCConvertiblePreferredStockMember" name="SeriesCConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_PeriodEndExchangeRateMember" name="PeriodEndExchangeRateMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_RUBMember" name="RUBMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_AveragePeriodExchangeRateMember" name="AveragePeriodExchangeRateMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_CommonStockIssuableUponConversionOfConvertibleDebtAndAccruedInterestMember" name="CommonStockIssuableUponConversionOfConvertibleDebtAndAccruedInterestMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_WarrantsToPurchaseCommonStockMember" name="WarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_WarrantsToPurchaseSeriesAConvertiblePreferredStockMember" name="WarrantsToPurchaseSeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_TwoThousandAndSeventeenVendorServicesMember" name="TwoThousandAndSeventeenVendorServicesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_SecuritiesPurchaseAndLoanAgreementsMember" name="SecuritiesPurchaseAndLoanAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_TwothousandAndNineteenShortTermNotesMember" name="TwothousandAndNineteenShortTermNotesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_LendersMember" name="LendersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_ClassBWarrantsMember" name="ClassBWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_ExtensionAgreementMember" name="ExtensionAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_NoteholdersMember" name="NoteholdersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_OtherNoteholdersMember" name="OtherNoteholdersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_ConvertibleNotePayableMember" name="ConvertibleNotePayableMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_NotePayableMember" name="NotePayableMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_OutofperiodAdjustmentAbstract" name="OutofperiodAdjustmentAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_NotesPayableRelatedPartyAbstract" name="NotesPayableRelatedPartyAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_OutofperiodAdjustmentDetailsNarrativeAbstract" name="OutofperiodAdjustmentDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item"/>
<element id="ACCP_NotesPayableRelatedPartyDetailsNarrativeAbstract" name="NotesPayableRelatedPartyDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item"/>
</schema>

↑Top
Filing Submission 0001493152-20-006905   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Mon., Apr. 29, 6:52:21.1am ET